Change of https://www.gov.uk/government/publications/somapacitan-lonapegsomatropin-and-somatrogon-acmd-advice

Change description : 2026-02-23 12:00:00: Added link to government response. [News and communications]

Showing diff : 2025-08-13 14:02:38.447290885 +00:00..2026-02-23 12:02:27.461394131 +00:00

Correspondence

Somapacitan, lonapegsomatropin and somatrogon: ACMD advice

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.

From:
Advisory Council on the Misuse of Drugs
Published
13 August 2025
Last updated
23 February 2026 — See all updates

Documents

ACMD advice on somapacitan, lonapegsomatropin and somatrogon (accessible)

HTML

ACMD advice on somapacitan, lonapegsomatropin and somatrogon

PDF, 141 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Somapacitan, lonapegsomatropin and somatrogon have been granted a marketing authorisation in the UK. This letter provides advice on their classification and scheduling.

Read the government response to the 3 ACMD reports on medicines.

Updates to this page

Published 13 August 2025
Last updated 23 February 2026 href="#full-history">+ show all updates

  1. Added link to government response.

  2. First published.

Sign up for emails or print this page

Update history

2026-02-23 12:00
Added link to government response.

2025-08-13 15:00
First published.